The aim of the study was to evaluate the influence of high values of blood pressure on circulating CXCL10. CXCL10 levels (median; interquartile range (IQR)) were significantly higher in patients with high systolic and diastolic blood pressure (n ¼ 48; 159 (125-185) pg ml À1 ) than in controls (n ¼ 127; 98 (71-115) pg ml À1 ) or in patients with only systolic hypertension (n ¼ 79; 125 (84-187) pg ml À1 ) (Po0.0001); in multiple linear regression models using CXCL10 as dependent variable, and age and systolic or diastolic blood pressure as covariates, only systolic or diastolic blood pressures were significantly (Po0.0001) related to CXCL10 levels. The results of this study demonstrate increased serum CXCL10 levels in patients with hypertension.
Recent experimental evidence demonstrating that inflammation is involved in the initiation and development of hypertension has lead to the response-to-injury hypothesis of atherosclerosis. [1] [2] [3] Furthermore, chemokines have been involved in the formation of atherosclerotic lesions in humans. 4 It is known that hypertension exerts a proinflammatory action by increasing free-radical formation, leukocyte adhesion and chemokine production by the endothelium. 1 In fact, patients with mild to moderate arterial hypertension without coronary artery disease have elevated serum levels of CC (group of chemokines with adjacent cysteines) chemokines MCP-1, MIP-1a and regulated on activation, normal T cell-expressed and secreted (RANTES). 5 The CXC chemokines inducible by interferong(CXCL9, CXCL10, CXCL11) are associated with Th1-mediated immune responses. Among them, CXCL10 is a more specific and reliable parameter, and its serum levels were found to be increased in several autoimmune and chronic inflammatory diseases. 6, 7 In a previous study aimed to evaluate the influence of aging 'per se' on serum CXCL10 levels, we observed that high CXCL10 levels were associated with higher systolic and overall diastolic blood pressure, in a small number of subjects. 8 Furthermore, CXCL10 has been found to be secreted by endothelial cells (one of the main cell targets of early-hypertension damage) under the influence of other cytokines and in response to different stimuli. 9 Regarding the other CXC chemokines, there is only one previous report that demonstrates a correlation between serum I-TAC/CXCL11 levels and the development of transplant coronary artery disease in humans; 10 however, the effect of blood pressure was not investigated.
The aim of this study was to evaluate a possible association between high blood pressure and circulating CXCL10 in subjects of the general population. The study group was selected from a populationbased survey of thyroid disorders 8 and encompassed 127 subjects, 60 males (M) and 67 females (F), affected by newly diagnosed, untreated essential hypertension. Each patient eligible for the study was randomly matched, by gender and age ( ± 2 years), one-to-one with a control group of subjects of the same background population with normal blood pressure. 8 Mandatory inclusion criteria for patients and controls were: (1) exclusion, by history and physical examination of clinically evident autoimmune disorders, or other inflammatory, allergic or chronic diseases, or treatment with any kind of drugs; (2) exclusion of any thyroid disorders (normal thyroid-stimulating hormone, thyroid hormones and thyroid autoantibodies) and any cardiovascular disease (by history and clinical examination).
Measurement of blood pressure was performed by mercury sphygmomanometer, in the morning, after a 12 h fasting. Blood pressure values were determined as the mean of two measurements at 3-min intervals after 10-min-seating. Diagnosis of hypertension was made when systolic blood pressure was 4140 mm Hg and diastolic blood pressure was 490 mm Hg.
Blood samples were collected in the morning, after overnight fasting, and serum was kept frozen until the measurement of CXCL10, fasting plasma glucose, serum total cholesterol, high-density lipoprotein, low-density lipoprotein, triglycerides, thyroid hormones, thyroid-stimulating hormone and thyroid autoantibodies.
All subjects gave their informed consent to enter the study, which was approved by the local Ethical Committee.
Serum CXCL10 levels were assayed by a quantitative sandwich immunoassay using a commercially available kit (R&D Systems, Minneapolis, MN, USA), with an analytical sensitivity ranging from 0.41-4.46 pg ml À1 and a mean minimum detectable level of 1.67 pg ml À1 . The intra and interassay coefficients of variation were 3.0 and 6.9%, respectively.
The
Simple regressions, using CXCL10(log(pg ml À1 )) as dependent variable and the other variables as independent variables, were performed. Multiple linear regression models, using CXCL10(log(pg ml À1 )) as dependent variable, and age, systolic or diastolic blood pressure as covariates, were performed.
The demographic and clinical features of controls and patients with hypertension are reported in Table 1 ; CXCL10 serum levels were significantly higher in patients with hypertension than in controls.
Among subjects with high blood pressure, 79 had isolated systolic hypertension (36F/43M; age 63 ± 8 years; systolic blood pressure, 156 ± 13 mm Hg; diastolic blood pressure, 84 ± 5 mm Hg), while 48 had systo-diastolic hypertension (24F/24M; age 62 ± 7 years; systolic blood pressure, 158 ± 22 mm Hg; diastolic blood pressure, 98 ± 6 mm Hg). The serum levels of CXCL10 were significantly higher in patients with high systolic and diastolic blood pressure (159, (125-185) pg ml À1 ) as compared to controls (98, (71-115) pg ml À1 ) or patients with only systolic hypertension (125, (84-187) pg ml À1 ) (Kruskal-Wallis, Po0.0001) (Mann-Whitney U test: normal vs systolic, P ¼ 0.0002; normal vs systo-diastolic, Po0.0001; systolic vs systo-diastolic, P ¼ 0.004).
Simple regression showed that CXCL10(log(pg ml À1 )) was significantly related to age (r ¼ 0.183, P ¼ 0.01), systolic blood pressure (r ¼ 0.329, Po0.0001) or diastolic blood pressure (r ¼ 0.364, Po0.0001), but not to the other studied parameters.
In multiple linear regression models using CXCL10(log(pg ml À1 )) as dependent variable, and age, systolic or diastolic blood pressure as covariates, only systolic (R 2 ¼ 0.114; Po0.0001), or diastolic blood pressure (R 2 ¼ 0.138; Po0.0001) were significantly related to CXCL10 levels. This is the first study demonstrating increased serum CXCL10 levels in patients with hypertension. In our series of patients, by using a multiple regression model, it was shown that only serum CXCL10 levels are positively associated with high systolic or diastolic blood pressure. This would suggest that serum CXCL10 levels do not simply reflect the coexistence of atherosclerosis, but are specifically associated with high blood pressure. In our series of hypertensive patients, we observed high levels of lipids with respect to controls, but none of the lipid parameters were related to CXCL10. However, we cannot completely exclude that lipids may contribute to the inflammation status of patients with hypertension. A potential limitation of the current study is the lack of identification of the source and the physiopathological mechanisms responsible for CXCL10 production in patients with hypertension. However, it is likely that the hyperexpression of different chemokines in hypertension may share common mechanisms. In fact, physical forces, such as high pressure and mechanical stretch 'per se', can induce MCP-1 secretion. 11 So, we can speculate that endothelial cells may produce CXCL10 under the influence of physical forces secondary to high blood pressure. However, the strongest argument supporting the role of high CXCL10 levels in hypertension is provided by a recent study demonstrating that inhibition of nuclear factor-kB (that resides into endothelial and smooth muscle cells, and is responsible for the activation of CXCL10 gene) activity ameliorates vascular inflammation and protects against angiotensin II-induced end-organ damage in rats. 12 However, other in vitro and in vivo studies will be necessary to evaluate if the association between hypertension and high CXCL10 has a physiopathological meaning in the pathogenesis of essential hypertension.
In conclusion, the results of this study demonstrate that serum CXCL10 levels are increased in patients with hypertension. Future longitudinal studies will be necessary to establish whether high serum CXCL10 in hypertension is associated to a more severe or rapid progression of the disease or to a different response to the pharmacological treatment. 
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